Navigation Links
New Bone Drug May Prevent Fractures But Raise Clot Risk
Date:2/24/2010

It's too soon to say if it outperforms existing drugs, expert says

WEDNESDAY, Feb. 24 (HealthDay News) -- A new drug to fight osteoporosis, the bone condition associated with aging and debilitating fractures, reduces the risk of fractures and the risk of some breast cancers, heart disease and stroke, according to a new study.

But, like other anti-osteoporosis drugs already on the market, the drug -- called lasofoxifene -- also boosts the risk of blood clots, the researchers found. Lasofoxifene, proposed brand name Fablyn, is not yet approved by the U.S. Food and Drug Administration.

Overall, lasofoxifene looks good, according to lead study author Dr. Steven Cummings, professor and director of the San Francisco Coordinating Center at the University of California San Francisco.

But Dr. Carolyn Becker, who wrote an editorial accompanying the study published in the Feb. 25 issue of the New England Journal of Medicine, is taking a wait-and-see approach. "It may turn out to be a dynamite drug, but it's not anything I would rush in to use as a clinician," she said. "There are too many unknowns."

For the study, Cummings and his team assigned 8,556 women who were aged 59 to 80 and had osteoporosis to take a daily dose of the drug (either 0.25 or 0.5 milligrams a day) or a placebo for five years. All had a bone mineral density T score of minus 2.5, considered osteoporosis.

The new drug is in a class of medications known as selective estrogen-receptor modulators (SERM), which act like estrogen in some tissues but anti-estrogen in other. "They act like estrogens when binding to bone cells and don't act like estrogen in the breast [thus not 'feeding' any cancers of the breast]," Cummings said.

Another SERM, already on the market, is raloxifene (Evista).

In the study, the researchers found that lasofoxifene "reduces the risk of all fractures (spinal and elsewhere), breast cancer, heart disease and stroke," Cummings said. "Breast cancer by more than half, nonspinal fractures by about a quarter, which is similar to what other drugs have done, stroke and heart disease by a quarter to a third."

The results he cites are all for the higher dose, 0.5 milligrams a day, when compared to placebo. The higher dose worked better, they found, and is the dose planned for clinical use.

When Cummings looked at adverse events during the follow-up, he found deaths were comparable in the high-dose and placebo group (73 and 65), but more deaths occurred in the low-dose group (90) from any cause.

More women taking the drug developed lung cancer, too -- 28 compared to four in the placebo group. Cummings said that may be related to chance.

Blood clot risk more than doubled on the drug, they found, a risk similar to what is found with estrogen and other SERMs, although the absolute risk was still small.

"The big news for osteoporosis is that lasofoxifene also prevents the fractures that cause most of the disability," Cummings said, referring to non-spinal fractures such as hip, upper arm and pelvis.

But Becker pointed out in her editorial that this effect did not kick in until five years, and the absolute risk reductions were small.

Women with osteoporosis should first consider drugs known as bisphosphonates (Fosamax and others), Cummings said, turning to SERM drugs if they are considered at higher risk.

Cummings has reported receiving consulting fees from pharmaceutical companies including Pfizer, which is developing Fablyn. Becker reports no disclosures.

More information

To learn more about medications for osteoporosis, visit the National Osteoporosis Foundation.



SOURCES: Steven R. Cummings, M.D., professor, director, San Francisco Coordinating Center, University of California, San Francisco; Carolyn Becker, M.D., associate professor, medicine, Harvard Medical School and Brigham and Women's Hospital, Boston; Feb. 25, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Psychiatrys main method to prevent mistaken diagnoses of depression doesnt work: NYU study
2. Bitrex Bitter Safety Additive Exhibiting at the Safe Kids Fair 2010; Making a Bitter Face to Learn about Poisoning Prevention
3. AT&T Foundations $50,000 Donation to National Health Foundation Supports Teen Pregnancy Prevention Program
4. African-Americans attitudes about lung cancer may hinder prevention
5. Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention
6. New Safety Bath and Sill Mats Help Prevent Slip and Fall in Bathrooms - from Martinson-Nicholls
7. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
8. VIDEO from Medialink and AAFA: Asthma PSA Reinforces Prevention of Asthma Symptoms
9. Medical Nurse Training, Inc. Partners With Healthcare Companies to Develop Corporate Branded, Accredited Programs for Patient/Bed Safety and Fall Prevention/Protection
10. Botox May Prevent Some Migraines
11. Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... NJ (PRWEB) , ... December 08, 2016 , ... CURE ... cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to ... making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... 08, 2016 , ... Today’s patients are encouraged to be ... SIGVARIS has created a new line of anti-embolism stockings to help prevent a ... benefits of graduated compression when transitioning from recovery to early rehabilitation. , The ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: